JP2016513082A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513082A5
JP2016513082A5 JP2015555409A JP2015555409A JP2016513082A5 JP 2016513082 A5 JP2016513082 A5 JP 2016513082A5 JP 2015555409 A JP2015555409 A JP 2015555409A JP 2015555409 A JP2015555409 A JP 2015555409A JP 2016513082 A5 JP2016513082 A5 JP 2016513082A5
Authority
JP
Japan
Prior art keywords
chain region
clostridium botulinum
neurotoxin
type
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015555409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/013385 external-priority patent/WO2014117148A1/en
Publication of JP2016513082A publication Critical patent/JP2016513082A/ja
Publication of JP2016513082A5 publication Critical patent/JP2016513082A5/ja
Pending legal-status Critical Current

Links

JP2015555409A 2013-01-28 2014-01-28 無毒性神経毒誘導体を用いる治療方法 Pending JP2016513082A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361757478P 2013-01-28 2013-01-28
US61/757,478 2013-01-28
PCT/US2014/013385 WO2014117148A1 (en) 2013-01-28 2014-01-28 Treatment methods using atoxic neurotoxin derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019130015A Division JP6877780B2 (ja) 2013-01-28 2019-07-12 無毒性神経毒誘導体を用いる治療方法

Publications (2)

Publication Number Publication Date
JP2016513082A JP2016513082A (ja) 2016-05-12
JP2016513082A5 true JP2016513082A5 (https=) 2017-05-25

Family

ID=51223179

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015555409A Pending JP2016513082A (ja) 2013-01-28 2014-01-28 無毒性神経毒誘導体を用いる治療方法
JP2019130015A Expired - Fee Related JP6877780B2 (ja) 2013-01-28 2019-07-12 無毒性神経毒誘導体を用いる治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019130015A Expired - Fee Related JP6877780B2 (ja) 2013-01-28 2019-07-12 無毒性神経毒誘導体を用いる治療方法

Country Status (5)

Country Link
US (2) US9315549B2 (https=)
EP (1) EP2948174B1 (https=)
JP (2) JP2016513082A (https=)
DK (1) DK2948174T3 (https=)
WO (1) WO2014117148A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
WO2011091419A2 (en) * 2010-01-25 2011-07-28 New York Universiy Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
WO2014117148A1 (en) * 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
CN107108703B (zh) 2015-01-09 2022-09-23 益普生生物创新有限公司 阳离子神经毒素
US20180140685A1 (en) * 2015-04-24 2018-05-24 Consiglio Nazionale Delle Ricerche A new therapeutic use of the botulinum neurotoxin serotype a
EP3263710A1 (en) * 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2020146458A1 (en) 2019-01-11 2020-07-16 Mayo Foundation For Medical Education And Research Micro-invasive surgical device and methods of use
WO2020243412A1 (en) 2019-05-29 2020-12-03 Mayo Foundation For Medical Education And Research Micro-invasive surgical device and methods of use
WO2022150837A1 (en) 2021-01-08 2022-07-14 Sonex Health, Inc. Surgical cutting device for ultrasonic guided soft tissue surgery
USD989961S1 (en) 2021-04-30 2023-06-20 Sonex Health, Inc. Soft tissue cutting device
US12251122B2 (en) 2021-04-30 2025-03-18 Sonex Health, Inc. Cutting device for trigger finger and other soft tissues
EP4710889A2 (en) 2022-01-31 2026-03-18 Sonex Health, Inc. Trigger thumb treatment devices
EP4577132A1 (en) 2022-08-25 2025-07-02 Sonex Health, Inc. De quervain's treatment device

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237224A (en) 1974-11-04 1980-12-02 Board Of Trustees Of The Leland Stanford Jr. University Process for producing biologically functional molecular chimeras
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
GB8516442D0 (en) 1985-06-28 1985-07-31 Wellcome Found Cloned antigen
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7037680B2 (en) 1993-09-21 2006-05-02 The United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
EP0760681B1 (en) 1994-05-31 1999-09-01 Allergan, Inc Modification of clostridial toxins for use as transport proteins
WO1996005222A1 (en) 1994-08-08 1996-02-22 Wisconsin Alumni Research Foundation Purification and pharmaceutical compositions containing type g botulinum neurotoxin
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
JP2000510332A (ja) 1996-04-19 2000-08-15 ヘンリー エム．ジャクソン ファンデーション フォー ザ アドバンスメント オブ ミリタリー メディシン インチミンを単独で、または１以上の他の抗原との融合タンパク質として発現する宿主生物の投与による、免疫応答を刺激する方法
US5750383A (en) 1996-05-14 1998-05-12 Boyce Thompson Institute For Plant Research, Inc. Baculovirus cloning system
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US5939070A (en) 1996-10-28 1999-08-17 Wisconsin Alumni Research Foundation Hybrid botulinal neurotoxins
US6001806A (en) 1997-06-27 1999-12-14 Humn Genome Sciences, Inc. Interferon stimulating protein and uses thereof
US6037150A (en) 1997-08-21 2000-03-14 University Technologies International Inc. Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
US6051239A (en) 1997-10-20 2000-04-18 Thomas Jefferson University Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US6323023B1 (en) 1998-01-13 2001-11-27 Yissum Research Development Co., Ltd. Vectors containing nucleic acids coding for Arabidopsis thaliana endo-1,4-β-glucanase secretion signal peptide
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
WO2001018038A2 (en) 1999-08-20 2001-03-15 Imperial College Innovations Limited Isoforms of snare molecules and the uses thereof in modulation of cellular exocytosis
HK1046020B (en) 1999-08-25 2007-05-11 Allergan, Inc. Activatable recombinant neurotoxins
KR100545945B1 (ko) 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
US6852510B2 (en) 2000-07-03 2005-02-08 Gala Design Inc Host cells containing multiple integrating vectors
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US7691983B2 (en) 2000-07-21 2010-04-06 Allergan, Inc. Chimera botulinum toxin type E
US6831059B2 (en) 2000-10-20 2004-12-14 Allergan, Inc. Compositions and methods for treating gonadotrophin related illnesses
AU2002236526B9 (en) 2000-11-15 2008-05-01 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sol-fusin: use of GP64-6His to catalyze membrane fusion
US7223577B2 (en) 2000-11-17 2007-05-29 Allergan, Inc. Post-translational modifications and Clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7255865B2 (en) 2000-12-05 2007-08-14 Allergan, Inc. Methods of administering botulinum toxin
US6787517B1 (en) 2000-12-29 2004-09-07 Allergan, Inc. Agent and methods for treating pain
WO2002060936A2 (en) 2001-01-31 2002-08-08 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7332567B2 (en) 2001-08-28 2008-02-19 Allergan, Inc. Fret protease assays for clostridial toxins
EP1334729A1 (en) * 2002-02-07 2003-08-13 Botulinum Toxin Research Associates, Inc. Therapeutic use of non-neurotoxic clostridium botulinum toxin type C2
US20030219402A1 (en) 2002-02-14 2003-11-27 Rutter William J. Chimeric molecules for cleavage in a treated host
US20040101531A1 (en) 2002-04-16 2004-05-27 Roy Curtiss Immunogenic compositions and vaccines comprising carrier bacteria that secrete antigens
US20030229454A1 (en) 2002-05-06 2003-12-11 Reinherz Ellis L. Use of a computer to design a molecule
AU2003237346A1 (en) 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040018589A1 (en) 2002-07-25 2004-01-29 Jun Zhong Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
US20040115727A1 (en) 2002-12-11 2004-06-17 Allergan, Inc., A Corporation Evolved clostridial toxins with altered protease specificity
US7172764B2 (en) 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
BRPI0513850A (pt) 2004-07-26 2008-05-20 Merz Pharma Gmbh & Co Kgaa composição terapêutica com uma neurotoxina botulìnica
US20060024794A1 (en) 2004-07-30 2006-02-02 Shengwen Li Novel methods for production of di-chain botulinum toxin
JP2008508886A (ja) 2004-08-04 2008-03-27 アラーガン、インコーポレイテッド 活性ボツリヌス毒素ａ型の発現の最適化
US7199193B2 (en) 2004-09-28 2007-04-03 Dow Global Technologies, Inc. Polyethylene glycol compounds and process of making
JP4994241B2 (ja) * 2004-11-22 2012-08-08 ニューヨーク・ユニバーシティ 遺伝子操作されたクロストリジウム遺伝子、操作された遺伝子によりコードされるタンパク質、およびその使用
US8512984B2 (en) * 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
GB0610867D0 (en) 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
TWI332851B (en) 2007-04-27 2010-11-11 Dermato Plastica Beauty Dpb Co Ltd Volume adjustable, micro-injection device
US8586081B2 (en) 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
US9044477B2 (en) 2007-12-12 2015-06-02 Allergan, Inc. Botulinum toxin formulation
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
GB0903006D0 (en) * 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
WO2011091419A2 (en) 2010-01-25 2011-07-28 New York Universiy Recombinant derivatives of botulinum neurotoxins engineered for trafficking studies and neuronal delivery
WO2014117148A1 (en) * 2013-01-28 2014-07-31 New York University Treatment methods using atoxic neurotoxin derivatives

Similar Documents

Publication Publication Date Title
JP2016513082A5 (https=)
EP2903635B1 (en) Use of clostridium toxin derivatives for the treatment of pain
US10011823B2 (en) Engineered botulinum neurotoxin
US7709228B2 (en) Activatable recombinant neurotoxins
JP6378772B2 (ja) 慢性疼痛のためのマルチプロテアーゼ（ｍｕｌｔｉｐｒｏｔｅａｓｅ）治療薬
IL270769A (en) Cationic neurotoxins
JP2015519362A5 (https=)
EP2424884B1 (en) A novel subtype of clostridium botulinum neurotoxin type a and uses thereof
TW202027782A (zh) 包含外源性活化圈之梭狀芽孢桿菌神經毒素
US9314514B2 (en) Modified neurotoxins with poly-glycine and uses thereof
US20240327472A1 (en) Modified clostridial neurotoxins
JP2021514674A5 (https=)
AU2025202320A1 (en) Treatment of autonomic disorders with botulinum toxin
JP2024107016A (ja) ボツリヌス神経毒素ａサブタイプ６および薬理学的使用方法
US11453903B2 (en) Production of activated clostridial neurotoxins
RU2020131317A (ru) Биогибрид ботулинического нейротоксина
HK40129551A (en) Treatment of autonomic disorders
CN120282979A (zh) 包含活化内体蛋白酶裂解位点的梭菌神经毒素
Fernandez-Salas et al. Steward et al.
NZ747619B2 (en) Chimeric neurotoxins
NZ749400A (en) Production of activated clostridial neurotoxins
RU2019108257A (ru) Сконструированный ботулинический нейротоксин
NZ747619A (en) Chimeric neurotoxins
EA046580B1 (ru) Катионные нейротоксины